Prevention of Neisseria gonorrhoeae With Meningococcal B Vaccine: A Matched Cohort Study in Southern California. (1st June 2022)

• Record Type: Journal Article
• Authors: Bruxvoort, Katia J; Lewnard, Joseph A; Chen, Lie H; Tseng, Hung Fu; Chang, Jennifer; Veltman, Jennifer; Marrazzo, Jeanne; Qian, Lei
• Is Part Of: Clinical infectious diseases. Volume 76:Number 3(2023)
• Page Start: e1341
• Page End: e1349
• Publication Date: 2022-06-01
• Subjects: meningococcal B vaccine -- gonorrhea -- cohort study; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciac436
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Background: Neisseria gonorrhoeae is acquiring increasing resistance to available oral antibiotics, and current screening and treatment approaches have not decreased gonorrhea incidence. Although a gonorrhea-specific vaccine does not exist, N. gonorrhoeae shares much of its genome with Neisseria meningitidis, notably critical antigenic determinants including outer membrane vesicles (OMV). Prior observational studies have suggested that OMV-based meningococcal serogroup B vaccines confer protection against gonorrhea. Methods: We conducted a matched cohort study from 2016 to 2020 to examine the association of OMV-containing recombinant meningococcal serogroup B vaccine (4CMenB) with gonorrhea infection among teens and young adults at Kaiser Permanente Southern California. Recipients of 4CMenB were matched in a ratio of 1:4 to recipients of non–OMV-containing polysaccharide-conjugate vaccine targeting serotypes A, C, W, and Y (MenACWY) who had not received 4CMenB and were followed for incident gonorrhea. We used Cox proportional hazards regression to compare gonorrhea rates among recipients of 4CMenB vs MenACWY, adjusting for potential confounders. We conducted the same analysis with chlamydia as a negative control outcome. Results: The study included 6641 recipients of 4CMenB matched to 26 471 recipients of MenACWY. During follow-up, gonorrhea incidence rates per 1000 person-years (95% confidence intervals [CIs]) were 2.0 (1.3–2.8) for recipients of 4CMenB and 5.2 (4.6–5.8) for recipients of MenACWY. In adjusted analyses, gonorrhea rates were 46% lower among recipients of 4CMenB vs MenACWY (hazard ratio [HR], 0.54; 95% CI, .34–.86), but chlamydia rates were similar between vaccine groups (HR, 0.98; 95% CI, .82–1.17). Conclusions: These results suggest cross-protection of 4CMenB against gonorrhea, supporting the potential for vaccination strategies to prevent gonorrhea. Abstract : In this matched cohort study, recipients of meningococcal B vaccine containing outer membrane vesicles (4CMenB) had a lower rate of gonorrhea, but not chlamydia, compared with recipients of polysaccharide-conjugate vaccines targeting meningococcal serotypes A, C, W, and Y, suggesting 4CMenB confers protection against gonorrhea.